Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05836025 · ClinicalTrials.gov registry record · Phase 2
Effect of Rapamycin in Ovarian Aging
A Phase 2 study of Perimenopausal, sponsored by Columbia University.
- Active
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT05836025 is a Phase 2 study of Perimenopausal that is active but no longer recruiting, run by Columbia University. The registered enrollment target is 50 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05836025, a Phase 2 study of Perimenopausal, is active but no longer recruiting, sponsored by Columbia University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators are proposing a prospective, randomized, double-blind, placebo-controlled pilot study assessing the ability of low-dose rapamycin to delay ovarian aging in women. Animal studies have shown the potential of rapamycin in slowing or reversing some age-associated pathways.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Rapamycin
Study Locations (1)
New York
- Columbia University Irving Medical Center / NewYork-Presbyterian Hospital - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2023-06-01 |
| Est. Completion | 2026-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05836025
The ClinicalTrials.gov registry entry for NCT05836025 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Perimenopausal appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05836025 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT05836025 about?
NCT05836025 is a clinical study titled "Effect of Rapamycin in Ovarian Aging". The investigators are proposing a prospective, randomized, double-blind, placebo-controlled pilot study assessing the ability of low-dose rapamycin to delay ovarian aging in women. Animal studies have shown the potential of rapamycin in slowing or reversing some age-associated pathways.
What is the current status of trial NCT05836025?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2023-06-01. Estimated completion is 2026-09.
What conditions does trial NCT05836025 study?
This clinical trial studies the following conditions: Perimenopausal.
What interventions are being tested in trial NCT05836025?
The interventions under investigation include: Placebo (OTHER), Rapamycin (DRUG).
Who is sponsoring clinical trial NCT05836025?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05836025 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.